Abstract | OBJECTIVES: METHODS: RESULTS: After median follow-up of 8.1 yr, 185 cardiovascular-related deaths had occurred. No increase in cardiovascular mortality occurred for men receiving a longer duration of goserelin. At 5 yr, cardiovascular mortality for men receiving longer-term adjuvant goserelin was 5.9% versus 4.8% with short-term goserelin (Gray's p=0.16). In multivariate analyses, treatment arm was not significantly associated with increased risk of cardiovascular mortality (adjusted hazard ratio [HR]=1.09; 95% confidence interval [CI], 0.81-1.47; p=0.58; when censoring at time of salvage goserelin, HR=1.02, 95%CI, 0.73-1.43; p=0.9). Traditional cardiac risk factors, including age, prevalent CVD, and DM, were significantly associated with greater cardiovascular mortality. CONCLUSIONS: Longer duration of adjuvant GnRHa therapy does not appear to increase cardiovascular mortality in men with locally advanced prostate cancer.
|
Authors | Jason A Efstathiou, Kyounghwa Bae, William U Shipley, Gerald E Hanks, Miljenko V Pilepich, Howard M Sandler, Matthew R Smith |
Journal | European urology
(Eur Urol)
Vol. 54
Issue 4
Pg. 816-23
(Oct 2008)
ISSN: 0302-2838 [Print] Switzerland |
PMID | 18243498
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural)
|
Chemical References |
- Antineoplastic Agents, Hormonal
- Goserelin
- Flutamide
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents, Hormonal
(adverse effects)
- Cardiovascular Diseases
(mortality)
- Flutamide
(adverse effects)
- Goserelin
(adverse effects)
- Humans
- Male
- Middle Aged
- Multivariate Analysis
- Prostatic Neoplasms
(drug therapy)
- Time Factors
|